- Location
- Zug
- Workplace
- Onsite
- Type
- Full-time
- Department
- Commercial
- Seniority
- Director
- Education
- PhD
- Source
- Lever
Description
Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need.
As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more about our neuromuscular franchise at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.
Scholar Rock is seeking a senior medical affairs professional to advance muscle-targeted treatments for spinal muscular atrophy and other rare neuromuscular diseases. The role combines strategic thinking with operational excellence and will be a critical role in the EMEA organization to deliver on key medical priorities such as scientific engagement plans, regional evidence generation initiatives, among others
The successful candidate will engage the SMA and FSHD community to address specific needs, establish and solidify trust and evolve knowledge and care. They will act as key partner working closely with cross-functional stakeholders across geographies, leasing with global functions and supporting EMEA affiliates.
The ideal candidate combines deep rare disease expertise with a strong track record of leading high-impact medical initiatives and engaging effectively with a broad range of stakeholders. They bring experience at both country and regional EMEA level and are comfortable operating in a dynamic, entrepreneurial biotech environment.